Last reviewed · How we verify
TMC125
TMC125 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication.
TMC125 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication. Used for Treatment of HIV-1 infection.
At a glance
| Generic name | TMC125 |
|---|---|
| Sponsor | Tibotec Pharmaceuticals, Ireland |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | Reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
TMC125 works by binding to the reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA. This action inhibits the replication of the virus, thereby reducing the viral load in the body.
Approved indications
- Treatment of HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Dizziness
Key clinical trials
- TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants (PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants (PHASE1)
- Switch From Etravirine to Doravirine as a Part of Antiretroviral Combination
- Safety and Efficacy of Etravirine in Friedreich Ataxia Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TMC125 CI brief — competitive landscape report
- TMC125 updates RSS · CI watch RSS
- Tibotec Pharmaceuticals, Ireland portfolio CI